Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S MOTRIN versus EC NAPROSYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S MOTRIN versus EC NAPROSYN.
CHILDREN'S MOTRIN vs EC-NAPROSYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, fever, and inflammation.
Naproxen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day without prescription, extended release forms: 600-800 mg orally twice daily.
500-1000 mg orally twice daily; maximum 1500 mg/day.
None Documented
None Documented
2-4 hours in children; prolonged in neonates and hepatic impairment.
Terminal elimination half-life 12-17 hours (mean 14 hours); prolonged in elderly and renal impairment
Renal (90%) as inactive metabolites and conjugates; fecal (<5%).
Renal (95%) as unchanged drug (10%) and conjugated metabolites (60%) and other metabolites (25%); biliary/fecal (5%)
Category C
Category C
NSAID
NSAID